Literature DB >> 12039910

CD6: expression during development, apoptosis and selection of human and mouse thymocytes.

Nora G Singer1, David A Fox, Tariq M Haqqi, Laura Beretta, Judith S Endres, Susan Prohaska, Jane R Parnes, Jonathan Bromberg, R Michael Sramkoski.   

Abstract

CD6, a 130-kDa surface glycoprotein, is expressed primarily on cells of T lineage. A co-stimulatory role for CD6 in mature T cells has been shown, but the function of CD6 during thymocyte development is unknown. Since CD6 ligands are expressed on thymic epithelium, their interactions with CD6 could be important in thymic selection. In this report we show that CD6 is developmentally regulated in human and mouse thymocytes, and further demonstrate that increase in the level of CD6 expression correlates with expression of the selection marker CD69. We also show that activation via CD2 induces CD6 expression on mature human thymocytes and on a subset of immature human thymocytes that are resistant to apoptosis. In human and mouse thymocytes that express heterogeneous TCR, CD6 increases occur as double-positive thymocytes are selected to a single-positive stage. In contrast, in thymocytes from TCR transgenic mice, CD6 is barely increased following selection, suggesting that as functional avidity increases, requirements for CD6-dependent co-stimulation decrease. Taken together, these results indicate that during thymic development CD6-dependent signals may contribute both to thymocyte survival, and to the overall functional avidity of selection in both man and mouse.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039910     DOI: 10.1093/intimm/dxf025

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  25 in total

1.  A conserved enhancer element differentially regulates developmental expression of CD5 in B and T cells.

Authors:  Robert Berland; Steven Fiering; Henry H Wortis
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

2.  CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors:  P Nair; R Melarkode; D Rajkumar; E Montero
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

3.  Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Authors:  Lazaro E Aira; Patricia Hernández; Dinorah Prada; Araceli Chico; Jorge A Gómez; Zuyén González; Karla Fuentes; Carmen Viada; Zaima Mazorra
Journal:  MAbs       Date:  2015-10-15       Impact factor: 5.857

4.  The role of CD6 in autoimmune diseases.

Authors:  David A Fox
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

5.  Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6.

Authors:  Yan Li; Jeffrey H Ruth; Stephanie M Rasmussen; Kalana S Athukorala; Daniel P Weber; M Asif Amin; Phillip L Campbell; Nora G Singer; David A Fox; Feng Lin
Journal:  Arthritis Rheumatol       Date:  2020-08-14       Impact factor: 10.995

6.  CD6 as a potential target for treating multiple sclerosis.

Authors:  Yan Li; Nora G Singer; Joy Whitbred; Michael A Bowen; David A Fox; Feng Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-16       Impact factor: 11.205

7.  Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes.

Authors:  Herbert G Kasler; Eric Verdin
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

8.  Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.

Authors:  Lazaro E Aira; Alejandro López-Requena; Dasha Fuentes; Liset Sánchez; Teresita Pérez; Aleida Urquiza; Heber Bautista; Leopoldina Falcón; Patricia Hernández; Zaima Mazorra
Journal:  MAbs       Date:  2014-03-04       Impact factor: 5.857

9.  Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).

Authors:  Christelle Le Dantec; Ruby Alonso; Tinhinane Fali; Enrique Montero; Valérie Devauchelle; Alain Saraux; Jacques-Olivier Pers; Yves Renaudineau
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

10.  A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Authors:  Pedro C Rodriguez; Roberto Torres-Moya; Gil Reyes; Claudino Molinero; Dinorah Prada; Ana M Lopez; Isabel M Hernandez; Maria V Hernandez; Jose P Martinez; Xochel Hernandez; Angel Casaco; Mayra Ramos; Yisel Avila; Yinet Barrese; Enrique Montero; Patricia Hernandez
Journal:  Results Immunol       Date:  2012-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.